Published in Arthritis Rheum on January 01, 2001
Expression and activity of citrullinating peptidylarginine deiminase enzymes in monocytes and macrophages. Ann Rheum Dis (2004) 2.82
Ectopic lymphoid structures support ongoing production of class-switched autoantibodies in rheumatoid synovium. PLoS Med (2009) 2.19
Autoantibody systems in rheumatoid arthritis: specificity, sensitivity and diagnostic value. Arthritis Res (2001) 2.18
Citrullinated proteins: sparks that may ignite the fire in rheumatoid arthritis. Arthritis Res Ther (2004) 2.05
Citrullinated proteins have increased immunogenicity and arthritogenicity and their presence in arthritic joints correlates with disease severity. Arthritis Res Ther (2005) 2.03
CD40 and autoimmunity: the dark side of a great activator. Semin Immunol (2009) 1.80
Structure and pathogenicity of antibodies specific for citrullinated collagen type II in experimental arthritis. J Exp Med (2009) 1.68
Antibodies to citrullinated human fibrinogen (ACF) have diagnostic and prognostic value in early arthritis. Ann Rheum Dis (2005) 1.57
Autoantibodies in rheumatoid arthritis: rheumatoid factors and anticitrullinated protein antibodies. QJM (2009) 1.13
A HEV-restricted sulfotransferase is expressed in rheumatoid arthritis synovium and is induced by lymphotoxin-alpha/beta and TNF-alpha in cultured endothelial cells. BMC Immunol (2005) 1.10
The relevance of citrullinated vimentin in the production of antibodies against citrullinated proteins and the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford) (2011) 1.07
Interleukin 10 promoter microsatellite polymorphisms are associated with response to long term treatment with etanercept in patients with rheumatoid arthritis. Ann Rheum Dis (2004) 1.06
Elevated autoantibody content in rheumatoid arthritis synovia with lymphoid aggregates and the effect of rituximab. Arthritis Res Ther (2008) 1.05
Anti-Sa antibodies: prognostic and pathogenetic significance to rheumatoid arthritis. Arthritis Res Ther (2004) 0.98
Prevalence and clinical significance of anti-cyclic citrullinated peptide antibodies in juvenile idiopathic arthritis. Ann Rheum Dis (2002) 0.95
Role of B cells in systemic lupus erythematosus and rheumatoid arthritis. Curr Opin Immunol (2008) 0.93
The effect of targeted rheumatoid arthritis therapies on anti-citrullinated protein autoantibody levels and B cell responses. Clin Exp Immunol (2013) 0.93
Functional role of dimerization of human peptidylarginine deiminase 4 (PAD4). PLoS One (2011) 0.91
Follicular dendritic cells in health and disease. Front Immunol (2012) 0.90
Recognition of new citrulline-containing peptide epitopes by autoantibodies produced in vivo and in vitro by B cells of rheumatoid arthritis patients. Immunology (2014) 0.89
Association of TBX21 polymorphisms in a Korean population with rheumatoid arthritis. Exp Mol Med (2009) 0.88
Differential responsiveness to immunoablative therapy in refractory rheumatoid arthritis is associated with level and avidity of anti-cyclic citrullinated protein autoantibodies: a case study. Arthritis Res Ther (2007) 0.86
Autoantibodies to posttranslational modifications in rheumatoid arthritis. Mediators Inflamm (2014) 0.86
Inflammatory lesions in the bone marrow of rheumatoid arthritis patients: a morphological perspective. Arthritis Res Ther (2012) 0.86
Cartilage oligomeric matrix protein specific antibodies are pathogenic. Arthritis Res Ther (2012) 0.86
Anti-cyclic citrullinated Peptide antibody is associated with interstitial lung disease in patients with rheumatoid arthritis. PLoS One (2014) 0.86
Diagnostic value of synovial fluid anti-cyclic citrullinated peptide antibody for rheumatoid arthritis. Rheumatol Int (2009) 0.86
CD154: an immunoinflammatory mediator in systemic lupus erythematosus and rheumatoid arthritis. Clin Dev Immunol (2011) 0.81
Molecular dynamics exposes alpha-helices in myelin basic protein. J Mol Model (2003) 0.80
The immunopathogenesis of seropositive rheumatoid arthritis: from triggering to targeting. Nat Rev Immunol (2016) 0.80
Cellular and molecular perspectives in rheumatoid arthritis. Semin Immunopathol (2017) 0.79
Mechanisms leading from systemic autoimmunity to joint-specific disease in rheumatoid arthritis. Nat Rev Rheumatol (2016) 0.79
In vitro eradication of citrullinated protein specific B-lymphocytes of rheumatoid arthritis patients by targeted bifunctional nanoparticles. Arthritis Res Ther (2016) 0.77
Serum anti-modified citrullinated vimentin antibody concentration is associated with liver fibrosis in patients with chronic hepatitis. Hepat Med (2011) 0.76
Putative IL-10 Low Producer Genotypes Are Associated with a Favourable Etanercept Response in Patients with Rheumatoid Arthritis. PLoS One (2015) 0.76
What is the ability of anti-cyclic citrullinated peptide antibodies determination in synovial fluid in discriminating rheumatoid arthritis from non-rheumatoid arthritis patients? A Tunisian cross-sectional study. Clin Rheumatol (2011) 0.75
Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med (2000) 16.20
Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum (1998) 8.69
The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum (2000) 8.64
Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum (2005) 8.47
The CD40 antigen and its ligand. Annu Rev Immunol (1994) 7.26
Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet (1994) 7.04
Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest (1998) 6.92
Genetic influence on cytokine production and fatal meningococcal disease. Lancet (1997) 4.89
A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford) (2003) 4.86
Cyclosporin A specifically inhibits function of nuclear proteins involved in T cell activation. Science (1989) 4.70
Identification of the RNA binding segment of human U1 A protein and definition of its binding site on U1 snRNA. EMBO J (1989) 4.69
Major determinants of the specificity of interaction between small nuclear ribonucleoproteins U1A and U2B'' and their cognate RNAs. Nature (1990) 4.67
Polymyositis: an overdiagnosed entity. Neurology (2003) 4.36
Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am J Med (2001) 4.31
Shoulder disorders in general practice: incidence, patient characteristics, and management. Ann Rheum Dis (1995) 4.30
The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum (2000) 4.10
Influence of non-inherited maternal HLA antigens on occurrence of rheumatoid arthritis. Lancet (1993) 3.87
Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to local disease activity. Arthritis Rheum (1997) 3.80
Transmission of signals from the T lymphocyte antigen receptor to the genes responsible for cell proliferation and immune function: the missing link. Annu Rev Immunol (1990) 3.55
Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. Ann Rheum Dis (2002) 3.53
cDNA cloning of the human U1 snRNA-associated A protein: extensive homology between U1 and U2 snRNP-specific proteins. EMBO J (1987) 3.47
Cell-specific expression of the carrot EP2 lipid transfer protein gene. Plant Cell (1991) 3.43
Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. Arthritis Rheum (2004) 3.38
Long-term course and outcome of functional capacity in rheumatoid arthritis: the effect of disease activity and radiologic damage over time. Arthritis Rheum (1999) 3.08
Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum (2004) 3.00
Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum (1996) 2.96
hnRNA and its attachment to a nuclear protein matrix. J Cell Biol (1981) 2.88
Expression and activity of citrullinating peptidylarginine deiminase enzymes in monocytes and macrophages. Ann Rheum Dis (2004) 2.82
Analysis of a cDNA clone expressing a human autoimmune antigen: full-length sequence of the U2 small nuclear RNA-associated B" antigen. Proc Natl Acad Sci U S A (1987) 2.75
European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis (2011) 2.74
Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol (1999) 2.74
The human U1 snRNP-specific U1A protein inhibits polyadenylation of its own pre-mRNA. Cell (1993) 2.58
Construction of cDNA coding for human von Willebrand factor using antibody probes for colony-screening and mapping of the chromosomal gene. Nucleic Acids Res (1985) 2.50
Synovial fluid T cell reactivity against 65 kD heat shock protein of mycobacteria in early chronic arthritis. Lancet (1988) 2.43
Detection of bacterial DNA in joint samples from patients with undifferentiated arthritis and reactive arthritis, using polymerase chain reaction with universal 16S ribosomal RNA primers. Arthritis Rheum (1998) 2.41
Factors predicting outcome of rheumatoid arthritis: results of a followup study. J Rheumatol (1993) 2.40
Full-length von Willebrand factor (vWF) cDNA encodes a highly repetitive protein considerably larger than the mature vWF subunit. EMBO J (1986) 2.35
Randomised placebo-controlled study of stopping second-line drugs in rheumatoid arthritis. Lancet (1996) 2.30
Reduction of synovial inflammation after anti-CD4 monoclonal antibody treatment in early rheumatoid arthritis. Arthritis Rheum (1995) 2.25
Asymptomatic synovitis precedes clinically manifest arthritis. Arthritis Rheum (1998) 2.24
Smoking is a risk factor for anti-CCP antibodies only in rheumatoid arthritis patients who carry HLA-DRB1 shared epitope alleles. Ann Rheum Dis (2005) 2.23
Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients. Ann Rheum Dis (2007) 2.22
A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford) (2000) 2.19
Fas ligation induces apoptosis of CD40-activated human B lymphocytes. J Exp Med (1995) 2.19
Interleukin 10 secretion in relation to human IL-10 locus haplotypes. Proc Natl Acad Sci U S A (1998) 2.18
Presence of bacterial DNA and bacterial peptidoglycans in joints of patients with rheumatoid arthritis and other arthritides. Arthritis Rheum (2000) 2.14
Interleukin-6 induced at mucosal surfaces by gram-negative bacterial infection. Infect Immun (1989) 2.13
The U2B'' RNP motif as a site of protein-protein interaction. EMBO J (1990) 2.12
Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum (2001) 2.11
Fine specificity of the anti-citrullinated protein antibody response is influenced by the shared epitope alleles. Arthritis Rheum (2007) 2.10
Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): A randomized, controlled trial. Arthritis Rheum (2008) 2.07
Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis (2006) 2.07
[Arthroscopic lavage plus corticosteroids is more effective than joint aspiration plus corticosteroids in patients with arthritis of the knee]. Ned Tijdschr Geneeskd (2008) 2.05
Relevance of the tumor necrosis factor alpha (TNF alpha) -308 promoter polymorphism in TNF alpha gene regulation. J Inflamm (1997) 2.05
Correlation of polymorphic variation in the promoter region of the interleukin-1 beta gene with secretion of interleukin-1 beta protein. Arthritis Rheum (2004) 2.05
Cross-linking of mRNA to proteins by irradiation of intact cells with ultraviolet light. Eur J Biochem (1980) 2.04
Shift toward T lymphocytes with a T helper 1 cytokine-secretion profile in the joints of patients with rheumatoid arthritis. Arthritis Rheum (1996) 2.03
Human U1 snRNP-specific C protein: complete cDNA and protein sequence and identification of a multigene family in mammals. Nucleic Acids Res (1988) 2.02
Effectiveness of corticosteroid injections versus physiotherapy for treatment of painful stiff shoulder in primary care: randomised trial. BMJ (1998) 2.00
The association of the U1-specific 70K and C proteins with U1 snRNPs is mediated in part by common U snRNP proteins. EMBO J (1994) 2.00
Decreased interleukin-10 and increased interleukin-12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis. Ann Neurol (1999) 1.99
Generation and application of type-specific anti-heparan sulfate antibodies using phage display technology. Further evidence for heparan sulfate heterogeneity in the kidney. J Biol Chem (1998) 1.97
The Leiden Early Arthritis Clinic. Clin Exp Rheumatol (2004) 1.97
Monospecific antibodies reveal details of U2 snRNP structure and interaction between U1 and U2 snRNPs. EMBO J (1986) 1.96
Validity and reliability of the twenty-eight-joint count for the assessment of rheumatoid arthritis activity. Arthritis Rheum (1995) 1.93
Antibodies against distinct nuclear matrix proteins are characteristic for mixed connective tissue disease. Clin Exp Immunol (1983) 1.92
Infliximab and methotrexate as induction therapy in patients with early rheumatoid arthritis. Arthritis Rheum (2007) 1.90
Early and aggressive treatment of rheumatoid arthritis patients affects the association of HLA class II antigens with progression of joint damage. Arthritis Rheum (2002) 1.87
hPop1: an autoantigenic protein subunit shared by the human RNase P and RNase MRP ribonucleoproteins. EMBO J (1996) 1.87
DAS-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis. Ann Rheum Dis (2010) 1.87
A critical evaluation of enzyme immunoassays for detection of antinuclear autoantibodies of defined specificities. I. Precision, sensitivity, and specificity. Arthritis Rheum (1999) 1.85
Characterization of the SS-B (La) antigen in adenovirus-infected and uninfected HeLa cells. EMBO J (1983) 1.83
Endothelial plasminogen activator inhibitor (PAI): a new member of the Serpin gene family. EMBO J (1986) 1.78
Diagnosis and course of early-onset arthritis: results of a special early arthritis clinic compared to routine patient care. Br J Rheumatol (1998) 1.78
Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005. Ann Rheum Dis (2005) 1.77
Analysis of protein--RNA interactions within Ro ribonucleoprotein complexes. Nucleic Acids Res (1991) 1.76
Patient-reported outcomes in a randomized trial comparing four different treatment strategies in recent-onset rheumatoid arthritis. Arthritis Rheum (2009) 1.76
Quantification of the cell infiltrate in synovial tissue by digital image analysis. Rheumatology (Oxford) (2000) 1.76
An IL-13 promoter polymorphism associated with increased risk of allergic asthma. Genes Immun (1999) 1.75
Analysis of heavy and light chain pairings indicates that receptor editing shapes the human antibody repertoire. J Mol Biol (1999) 1.75
Long term high intensity exercise and damage of small joints in rheumatoid arthritis. Ann Rheum Dis (2004) 1.73
Three novel components of the human exosome. J Biol Chem (2000) 1.72
Comparison of the responsiveness of the Harris Hip Score with generic measures for hip function in osteoarthritis of the hip. Ann Rheum Dis (2003) 1.71
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Ann Rheum Dis (2007) 1.70
Discovery of distinctive gene expression profiles in rheumatoid synovium using cDNA microarray technology: evidence for the existence of multiple pathways of tissue destruction and repair. Genes Immun (2003) 1.70
Antiperinuclear factor, a marker autoantibody for rheumatoid arthritis: colocalisation of the perinuclear factor and profilaggrin. Ann Rheum Dis (1991) 1.68
Clinical significance of rheumatoid factors in early rheumatoid arthritis: results of a follow up study. Ann Rheum Dis (1992) 1.68
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011. Ann Rheum Dis (2012) 1.67